laminaran has been researched along with Bacterial-Infections* in 2 studies
1 trial(s) available for laminaran and Bacterial-Infections
Article | Year |
---|---|
Infection prevention in patients with severe multiple trauma with the immunomodulator beta 1-3 polyglucose (glucan).
In a effect to prevent nosocomial pneumonia and sepsis, we treated patients with severe multiple trauma with an immunomodulator--beta 1-3 polyglucose (glucan). Forty-one patients with no infection at admission were stratified using Trauma Score and included in a randomized double-blind controlled trial. They were divided into a control group (n = 20) and a glucan group (n = 21). Pneumonia occurred in 11 of 20 patients in the control group and in two of 21 recipients of glucan (p < 0.01). Sepsis occurred in seven of 20 patients in the control group and in two of 21 patients treated with glucan (p < 0.05). Considering patients with pneumonia and sepsis, a decrease was observed in nosocomial infection from 65.0 to 14.4 percent (p < 0.001). The mortality rate related to infection was 30.0 percent in patients in the control group and 4.8 percent in the group treated with glucan (p < 0.05). The general mortality rate, cerebral deaths excluded, was 42.1 percent in the control group and 23.5 percent in the glucan group. Topics: Adjuvants, Immunologic; Adult; Bacterial Infections; beta-Glucans; Craniocerebral Trauma; Cross Infection; Double-Blind Method; Female; Glucans; Humans; Incidence; Male; Multiple Trauma; Pneumonia | 1993 |
1 other study(ies) available for laminaran and Bacterial-Infections
Article | Year |
---|---|
Early diagnosis of invasive candidiasis and rapid evaluation of antifungal therapy by combined use of conventional chromogenic limulus test and a newly developed endotoxin specific assay.
Since beta-1,3-glucan is a common component of fungal cell wall, its detection might be useful in diagnosing invasive candidiasis. Not only endotoxin but beta-1,3-glucan activates proclotting enzyme contained in a conventional chromogenic limulus test (CCLT). Endotoxin activates this enzyme through factor C, while the beta-1,3-glucan activates through factor G. Since endotoxin specific test (EST) contains factor C, endotoxin would be quantified. By subtracting EST value from CCLT value, beta-1,3-glucan would be quantified. We named this value Fungal Index (FI), and examined if it actually reflects the candidal infection. Ninety-two patients were tested for CCLT and EST prospectively. FI increased significantly in candidal infection (p less than 0.05) but remained low in GNR infection. Moreover, FI increased proportionally to the severity of candidal infection. Elevated FI decreased when antifungal therapy was successful. Thus FI was a useful index not only in the diagnosis of invasive candidiasis but also in the evaluation of antifungal therapy. Topics: Antifungal Agents; Bacterial Infections; beta-Glucans; Candidiasis; Chromogenic Compounds; Endotoxins; Escherichia coli; Glucans; Humans; Limulus Test; Mycology; Prospective Studies | 1988 |